These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 11369625)
1. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Karp JE; Lancet JE; Kaufmann SH; End DW; Wright JJ; Bol K; Horak I; Tidwell ML; Liesveld J; Kottke TJ; Ange D; Buddharaju L; Gojo I; Highsmith WE; Belly RT; Hohl RJ; Rybak ME; Thibault A; Rosenblatt J Blood; 2001 Jun; 97(11):3361-9. PubMed ID: 11369625 [TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Kurzrock R; Kantarjian HM; Cortes JE; Singhania N; Thomas DA; Wilson EF; Wright JJ; Freireich EJ; Talpaz M; Sebti SM Blood; 2003 Dec; 102(13):4527-34. PubMed ID: 12947010 [TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. Zujewski J; Horak ID; Bol CJ; Woestenborghs R; Bowden C; End DW; Piotrovsky VK; Chiao J; Belly RT; Todd A; Kopp WC; Kohler DR; Chow C; Noone M; Hakim FT; Larkin G; Gress RE; Nussenblatt RB; Kremer AB; Cowan KH J Clin Oncol; 2000 Feb; 18(4):927-41. PubMed ID: 10673536 [TBL] [Abstract][Full Text] [Related]
4. Farnesyl protein transferase inhibitors as targeted therapies for hematologic malignancies. Karp JE Semin Hematol; 2001 Jul; 38(3 Suppl 7):16-23. PubMed ID: 11523024 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Cortes J; Albitar M; Thomas D; Giles F; Kurzrock R; Thibault A; Rackoff W; Koller C; O'Brien S; Garcia-Manero G; Talpaz M; Kantarjian H Blood; 2003 Mar; 101(5):1692-7. PubMed ID: 12411300 [TBL] [Abstract][Full Text] [Related]
6. Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. Kurzrock R; Albitar M; Cortes JE; Estey EH; Faderl SH; Garcia-Manero G; Thomas DA; Giles FJ; Ryback ME; Thibault A; De Porre P; Kantarjian HM J Clin Oncol; 2004 Apr; 22(7):1287-92. PubMed ID: 15051776 [TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. Cohen SJ; Gallo J; Lewis NL; Alpaugh RK; Gentner L; Rogatko A; Yeslow G; Schol J; Verhaeghe T; Zannikos P; Palmer PA; Weiner LM; Meropol NJ Cancer Chemother Pharmacol; 2004 Jun; 53(6):513-8. PubMed ID: 14760509 [TBL] [Abstract][Full Text] [Related]
8. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Adjei AA; Croghan GA; Erlichman C; Marks RS; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Bruzek LM; Atherton P; Thibault A; Palmer PA; Kaufmann SH Clin Cancer Res; 2003 Jul; 9(7):2520-6. PubMed ID: 12855626 [TBL] [Abstract][Full Text] [Related]
9. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Le Gouill S; Pellat-Deceunynck C; Harousseau JL; Rapp MJ; Robillard N; Bataille R; Amiot M Leukemia; 2002 Sep; 16(9):1664-7. PubMed ID: 12200678 [TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. Crul M; de Klerk GJ; Swart M; van't Veer LJ; de Jong D; Boerrigter L; Palmer PA; Bol CJ; Tan H; de Gast GC; Beijnen JH; Schellens JH J Clin Oncol; 2002 Jun; 20(11):2726-35. PubMed ID: 12039935 [TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Punt CJ; van Maanen L; Bol CJ; Seifert WF; Wagener DJ Anticancer Drugs; 2001 Mar; 12(3):193-7. PubMed ID: 11290865 [TBL] [Abstract][Full Text] [Related]
12. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002. Caponigro F Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276 [TBL] [Abstract][Full Text] [Related]
13. Multifaceted approach to the treatment of bcr-abl-positive leukemias. O'Dwyer M Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Heymach JV; Johnson DH; Khuri FR; Safran H; Schlabach LL; Yunus F; DeVore RF; De Porre PM; Richards HM; Jia X; Zhang S; Johnson BE Ann Oncol; 2004 Aug; 15(8):1187-93. PubMed ID: 15277257 [TBL] [Abstract][Full Text] [Related]
15. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. Cohen SJ; Ho L; Ranganathan S; Abbruzzese JL; Alpaugh RK; Beard M; Lewis NL; McLaughlin S; Rogatko A; Perez-Ruixo JJ; Thistle AM; Verhaeghe T; Wang H; Weiner LM; Wright JJ; Hudes GR; Meropol NJ J Clin Oncol; 2003 Apr; 21(7):1301-6. PubMed ID: 12663718 [TBL] [Abstract][Full Text] [Related]
16. [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia]. Thomas X; Elhamri M Bull Cancer; 2005 Mar; 92(3):227-38. PubMed ID: 15820917 [TBL] [Abstract][Full Text] [Related]
17. Current status of clinical trials of farnesyltransferase inhibitors. Karp JE; Kaufmann SH; Adjei AA; Lancet JE; Wright JJ; End DW Curr Opin Oncol; 2001 Nov; 13(6):470-6. PubMed ID: 11673687 [TBL] [Abstract][Full Text] [Related]
18. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Alsina M; Fonseca R; Wilson EF; Belle AN; Gerbino E; Price-Troska T; Overton RM; Ahmann G; Bruzek LM; Adjei AA; Kaufmann SH; Wright JJ; Sullivan D; Djulbegovic B; Cantor AB; Greipp PR; Dalton WS; Sebti SM Blood; 2004 May; 103(9):3271-7. PubMed ID: 14726402 [TBL] [Abstract][Full Text] [Related]
19. Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Venkatasubbarao K; Choudary A; Freeman JW Cancer Res; 2005 Apr; 65(7):2861-71. PubMed ID: 15805288 [TBL] [Abstract][Full Text] [Related]
20. A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. Lancet JE; Duong VH; Winton EF; Stuart RK; Burton M; Zhang S; Cubitt C; Blaskovich MA; Wright JJ; Sebti S; Sullivan DM Clin Cancer Res; 2011 Mar; 17(5):1140-6. PubMed ID: 21233404 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]